This article is more than 5 years old. Information may no longer be current.

Bioptigen to receive $1.72 million in grants to develop OCT technology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bioptigen announced it will receive a total of $1.72 million in grants from the National Eye Institute for the development of microscope-integrated optical coherence tomography technology.

Under the terms of the grants, Bioptigen will develop a novel intraoperative OCT system that will be integrated directly into the optical train of the microscope, according to a company press release.

“The work advanced under these grants will bring surgeons one step closer to realizing the full value of intraoperative OCT,” Eric Buckland, OD, CEO of Bioptigen, said in the release. “Ultimately, the ability to observe subsurface structures simultaneous with surgical manipulations will provide surgeons with a critical advance in microscopic visualization.”

The design of the Microscope-Integrated SDOCT enables real-time imaging over a 20-mm-wide and 15-mm-deep field of view, offering independent OCT focus and zoom controls for improved flexibility in both posterior and anterior imaging.

The product is not cleared by the FDA to be marketed, sold or distributed in the United States, according to the release.